Coverage
-
November 06, 2020
In a pair of decisions on remand from the Federal Circuit, the Patent Trial and Appeal Board has upheld a claim in a patent covering Pfizer's blockbuster Prevnar 13 pneumonia vaccine, determining for the second time that Merck failed to show it was invalid as obvious.
1 other articles on this case.
View all »